This is an opportunity to better understand the genetic
architecture of Parkinson's disease in your country,
as
all recruited patients will undergo extensive genotyping
including testing for known mutations
in established
Parkinson's disease genes, as well as whole genome sequencing
and/or long-read sequencing in a selection of patients/families.
We encourage the submission of both patients
without a genetic diagnosis and those already known to carry
pathogenic variants in Parkinson's disease genes.
To submit a patient/family, go to
The two major aims of GP2 are to discover novel
genetic causes of Parkinson's disease and to better characterize
modifying factors influencing disease
manifestation and progression.
To address these aims, the Monogenic Hub will recruit
and
investigate Parkinson's disease patients with a potential
monogenic basis, e.g. those with early onset
(<50 years), positive family history, or atypical
clinical presentation,
with particular attention to
those originating from less well
studied
(underrepresented) populations.
This is an opportunity to better understand the genetic
architecture of Parkinson's disease in your country, as all
recruited patients will undergo extensive genotyping including
an
testing for known mutations in established Parkinson's disease
genes, as well as whole genome sequencing
and/or
long-read sequencing in a selection of patients/families.
We encourage the submission of both patients
without a genetic diagnosis and those already known to carry
pathogenic variants in Parkinson's disease genes.
To submit a patient/family, go to
For clinicians and researchers, this project provides a great
opportunity to better understand the genetic
architecture of PD
in their respective communities/countries,
in addition to
opportunities for scientific collaborations and joint
publications
and grants.
We encourage the submission of both patients
without a genetic diagnosis and those already known to carry
pathogenic variants
in Parkinson's disease genes
.
To submit a patient/family, go to
We encourage the submission of both patients
without a genetic diagnosis and those already known to carry
pathogenic variants in Parkinson's disease genes.
To submit a patient/family, go to
The two major aims of GP2
are to discover novel
genetic causes
of Parkinson's disease and to better characterize modifying
factors influencing disease manifestation
and
progression.
To address these aims, the Monogenic Hub will recruit
and investigate Parkinson's disease patients
with a
potential monogenic basis, e.g. those with early
onset (<50 years), positive family history,
or atypical clinical presentation, with
particular attention
to those originating from less well
studied
(underrepresented) populations.
The two major aims of GP2 are to discover novel
genetic causes of Parkinson's disease and to better characterize
modifying factors influencing disease
manifestation and progression.
To address these aims, the Monogenic Hub will recruit
and investigate Parkinson's disease patients
with a
potential monogenic basis, e.g. those with early
onset (<50 years), positive family history,
or atypical clinical presentation, with
particular attention to those originating from less well studied
(underrepresented) populations.
The two major aims of GP2 are to discover novel
genetic causes of Parkinson's disease and to better characterize
modifying factors influencing disease
manifestation and progression.
To address these aims, the Monogenic Hub will recruit
and investigate Parkinson's disease patients
with a
potential monogenic basis, e.g. those with early
onset (<50 years), positive family history,
or atypical clinical presentation, with
particular attention
to those originating from less well
studied(underrepresented) populations.
This is an opportunity to better understand the genetic
architecture of Parkinson's disease in your country,
as
all recruited patients will undergo extensive genotyping
including an testing for known mutations
in established
Parkinson's disease genes,
as well as whole genome
sequencing and/or long-read sequencing in a selection of
patients/families.
We encourage the submission of both patients
without a genetic diagnosis and those already known to carry
pathogenic variants in Parkinson's disease genes.
To submit a patient/family, go to
What are the benefits of contributing cases/families?
For patients, knowledge of one's genetic status can provide valuable
information regarding prognosis (likelihood of developing, or
passing on, the disease; disease course; etc.), which may be helpful
in life planning. It also opens up the possibility
of
participating in clinical trials or benefiting
from new genetics-based treatments.
Notably, all recruited patients will undergo extensive
genotyping including testing for known mutations
in
established Parkinson's disease genes (using
the Genome
Diversity Array, GDA), and a large proportion will also undergo
whole genome
and/or long-read sequencing.
For patients, knowledge of one's genetic status can provide valuable
information regarding prognosis (likelihood of developing, or
passing on, the disease; disease course; etc.), which may be helpful
in life planning.
It also opens up the possibility of
participating in clinical trials or benefiting
from new genetics-based treatments.
Notably, all recruited patients will undergo extensive
genotyping including testing
for known mutations in
established Parkinson's disease genes (using the Genome Diversity
Array, GDA), and a large proportion will also undergo whole
genome
and/or long-read sequencing.
For patients, knowledge of one's genetic status can provide valuable
information regarding prognosis (likelihood
of
developing, or passing on, the disease; disease course; etc.),
which may be helpful in life planning. It also
opens up
the possibility of participating in clinical trials
or benefiting
from new genetics-based
treatments.
Notably, all recruited patients will undergo extensive
genotyping including testing for known mutations in established
Parkinson's disease genes (using the Genome Diversity Array,
GDA),
and a large proportion will also undergo whole
genome
and/or long-read sequencing.
For clinicians and researchers, this project provides a
great opportunity to better understand the
genetic architecture of PD in their respective
communities/countries, in addition
to opportunities for
scientific collaborations and joint publications and grants.
For patients, knowledge of one's genetic status can provide valuable
information regarding prognosis (likelihood of developing, or
passing on, the disease; disease course; etc.), which may be helpful
in life planning. It also opens up the possibility
of
participating in clinical trials or benefiting
from
new genetics-based treatments.
Notably, all recruited patients will undergo extensive
genotyping including testing for known mutations in established
Parkinson's disease genes (using the Genome Diversity Array,
GDA),
and a large proportion will also undergo whole
genome and/or long-read sequencing.
The two major aims of GP2 are to discover novel
genetic causes of Parkinson's disease and to better characterize
modifying factors influencing disease
manifestation
and progression.
To address these aims, the Monogenic Hub will recruit
and investigate Parkinson's disease patients with a potential
monogenic basis, e.g. those with early onset
(<50 years), positive family history, or atypical
clinical presentation, with particular attention
to
those originating from less well studied (underrepresented)
populations.
The two major aims of GP2 are to discover novel
genetic causes of Parkinson's disease and to better characterize
modifying factors influencing disease
manifestation and progression.
To address these aims, the Monogenic Hub will recruit
and investigate Parkinson's disease patients with a potential
monogenic basis, e.g. those
with early
onset (<50 years), positive family history,
or atypical clinical presentation, with
particular attention to those originating from less well studied
(underrepresented) populations.
For patients, knowledge of one's genetic status can provide valuable
information regarding prognosis (likelihood
of
developing, or passing on, the disease; disease course; etc.),
which may be helpful in life planning. It also
opens up the possibility of participating in clinical trials
or benefiting from new genetics-based
treatments.
Notably, all recruited patients will undergoextensive
genotyping including testing for known mutations
in
established Parkinson's disease genes (using the Genome Diversity
Array, GDA),
and a large proportion will also undergo
whole genome and/or long-read
sequencing.
For clinicians and researchers,
this project
provides a great opportunity to better
understand the genetic architecture of PD in their respective
communities/countries,
in addition
to opportunities for scientific
collaborations and joint publications
and grants.
What
are the benefits
of contributing
cases/families?
We encourage the submission of both patients
without a genetic diagnosis
and those already known to
carry pathogenic variants in Parkinson's disease genes
.
To submit a patient/family, go to
What are the benefits
of contributing cases/families?
For clinicians and researchers, this project provides
a
great opportunity to better understand
the
genetic architecture of PD
in their respective
communities/countries, in addition to
opportunities
for scientific collaborations and joint
publications
and grants.
We encourage the submission of both patients
without
a genetic diagnosis and those already known to
carry pathogenic variants in Parkinson's disease genes
.
To submit a patient/family, go to
What are the benefits
of contributing cases/families?
For clinicians and researchers, this project provides
a
great opportunity to better understand
the
genetic architecture of PD
in their respective
communities/countries, in addition to
opportunities
for scientific collaborations and joint
publications
and grants.
We encourage the submission of both patients without a genetic
diagnosis and those already known to carry pathogenic variants
in Parkinson's disease genes.
To submit a patient/family, go to